Using the Hemoglobin Content of Reticulocytes (RET-He) to Evaluate Anemia in Patients With Cancer
|
|
- Rodger Wells
- 6 years ago
- Views:
Transcription
1 Using the Hemoglobin Content of Reticulocytes (RET-He) to Evaluate Anemia in Patients With Cancer Ellinor I. B. Peerschke, PhD, 1,2 Melissa S. Pessin, MD, PhD, 1 and Peter Maslak, MD 1,2 From the 1 Memorial Sloan-Kettering Cancer Center, New York, NY, and 2 Weill Cornell Medical College, New York, NY. Key Words: RET-He; Anemia; Iron deficiency; Cancer; Hematology Am J Clin Pathol October 2014;142: ABSTRACT Objectives: Evaluation of anemia, particularly iron deficiency, in patients with cancer is difficult. This study examined using the hemoglobin content of reticulocytes (RET-He) to rule out iron deficiency, as defined by serum iron studies (transferrin saturation <20%, serum iron <40 µg/ dl, and ferritin <100 ng/ml), in an unselected cancer patient population. Methods: Patients were entered into the study based on the existence of concurrent laboratory test requests for CBC and serum iron studies. Results: Using a threshold of 32 pg/cell, RET-He ruled out iron deficiency with a negative predictive value (NPV) of 98.5% and 100%, respectively, in the study population (n = 209) and in a subpopulation of patients with low reticulocyte counts (n = 19). In comparison, the NPV of traditional CBC parameters (hemoglobin, <11 g/dl; mean corpuscular volume, <80 fl) was only 88.5%. Conclusions: These results support the use of RET-He in the evaluation of iron deficiency in a cancer care setting. Advanced reticulocyte indices, such as the cellular hemoglobin content of reticulocytes, designated CHr and RET-He, are reportable parameters on Siemens ADVIA 2120 (Siemens, Tarrytown, NY) and Sysmex XE and XN series automated hematology analyzers (Sysmex, Lincolnshire, IL), 1 respectively, without additional blood requirements or technical intervention. Good agreement between CHr and RET-He measurements has been reported. 2-4 These indices correlate with iron-deficient erythropoiesis and are useful markers of iron deficiency in infants and children, 5 adult blood donors, 6 geriatric patients, 7,8 pregnant women, 9 and patients with chronic kidney disease undergoing hemodialysis. 3,4,8,10,11 In addition, the hemoglobin content of reticulocytes is a useful tool for monitoring patients response to iron replacement therapy 12,13 and detecting iron-restricted erythropoiesis in patients receiving erythropoietin therapy However, little is known about the utility of RET-He in the evaluation of complex anemias in malignancy. Although iron deficiency is the leading cause of anemia worldwide, the anemia of chronic disease is more common among patients with malignancies. In contrast to iron deficiency anemia caused by inadequate iron stores, the anemia of chronic disease is associated with decreased iron availability despite abundant stores The hemoglobin content of reticulocytes may assist in differentiating between these forms of anemia 22,23 and shows a lower degree of withinpatient variability than ferritin or other serum indicators of iron status. 24 In the current outpatient cancer care setting, assessing iron deficiency requires additional biochemical tests, results of which are not available in real time. Iron deficiency anemia may be inferred from limited information provided 506 Am J Clin Pathol 2014;142: Downloaded 506 from
2 by automated CBC and reticulocyte analysis, including hemoglobin (Hb), hematocrit, and RBC indices. However, measures of mature erythrocyte indices (mean corpuscular volume [MCV], mean corpuscular hemoglobin, and RBC distribution width) cannot detect early iron-deficient erythropoiesis due to the slow turnover of erythrocytes (~120 days) in circulation. 25 In contrast, the hemoglobin content of reticulocytes reflects the recent functional availability of iron 12,26-29 for erythropoiesis, and results are available in real time as part of automated reticulocyte analysis. The measurement is not affected by physiologic interferences, except in cases of thalassemia 30 and macrocytosis/megaloblastosis. 31 The present study, therefore, investigated RET-He, reported by the Sysmex XE 2100, as a tool to rapidly rule out iron deficiency, defined by results of serum iron studies in an outpatient oncology setting. Iron deficiency is associated with significant morbidity in oncology patients and is readily treated. Thus, the ability to assess iron deficiency, as part of automated CBC/reticulocyte analysis, may significantly enhance patient management, particularly in an outpatient setting. Since the etiology of anemia in patients with cancer is complex, involving cytopenias secondary to chemotherapy, bone marrow failure, chronic disease/inflammation, and/or iron deficiency, the goal of the present study was to establish an RET-He cutoff that could rapidly rule out iron deficiency. The data suggest that RET-He, at a threshold of 32 pg/cell, may be an important discriminator to rule out iron deficiency anemia in patients with cancer. Materials and Methods Patients and Blood Samples Remnant peripheral blood samples (n = 255), collected in EDTA anticoagulant, were retrieved from the Hematology Laboratory between May 25, 2012, and November 7, 2012, based on the existence of concurrent laboratory test requests for CBC analysis and ferritin, as well as sample availability within 6 hours of blood collection. In 209 cases, orders for ferritin were accompanied by orders for serum iron and transferrin saturation. RET-He was quantified using the Sysmex XE Chart review was undertaken to obtain laboratory test results and clinical diagnosis. The study population consisted of 114 males (aged 17 months to 94 years) and 95 females (aged years). Patients were entered into the study without regard for diagnosis or treatment and consisted of individuals with solid tumors or hematologic malignancies who were undergoing and/or recovering from diverse chemotherapy and/or radiation treatment regimens. This study was approved by the institutional review board of Memorial Sloan Kettering Cancer Center for the protection of human subjects. Although bone marrow examination is the conventional gold standard for assessing iron stores, it is not performed routinely at our center for the sole purpose of identifying iron deficiency because of its invasive nature. Thus, in the present study, iron deficiency anemia was defined biochemically using serum iron (<40 µg/dl), transferrin saturation (<20%), and Hb (<11 g/dl), with or without ferritin (<100 ng/ ml), as described previously, 2,20,21 consistent with current clinical practice recommendations. Transferrin saturation is a particularly useful biochemical marker of iron deficiency, since it reflects the interrelationship between bone marrow iron stores, iron absorption, and the availability of iron in circulating blood. 32 In contrast, ferritin is less useful in oncology patients due to its elevation in patients with diverse solid tumors and its association with more progressive disease and shorter survival when elevated. 33 Indeed, World Health Organization guidelines indicate that reliable assessment of iron status is not possible using ferritin in the presence of inflammation and infection. 34 Thus, the present study evaluated RET-He performance characteristics against biochemical markers of iron deficiency, including serum iron and transferrin saturation with and without ferritin. Statistical Analysis The ability of RET-He to identify iron deficiency in a diverse patient population with cancer was evaluated by calculating sensitivity, specificity, and positive and negative predictive values against routinely ordered serum iron studies as the diagnostic standard. Differences between selected data sets were evaluated by performing a t test for independent samples using Excel Windows 2010 (Microsoft, Redmond, WA). Statistical differences between data sets were defined by a P value less than.05. Results were not stratified by type of malignancy or evidence of marrow infiltration because of limited sample size. Results Table 1 summarizes major characteristics of the study population. Patients consisted of approximately equal numbers of males and females. The mean age of the female population was slightly younger than that of the male cohort (P =.006), and as expected, the mean Hb was slightly lower in females than in males (P =.013). However, a similar proportion of males and females were anemic based on thresholds of Hb of 12 g/dl and 11 g/dl, respectively. No differences in MCV, serum iron, transferrin saturation, or ferritin were noted. The distribution of RET-He values (pg) in the study population is illustrated in Figure 1. No differences were Downloaded from Am J Clin Pathol 2014;142:
3 Peerschke et al / RET-He and Anemia Table 1 Study Population Characteristics a Characteristic Male Female No. of patients Age, y 61.6 ± 20.4 b 53.9 ± 16.2 b Median age, y Hb, g/dl 11.8 ± 2.7 b 10.9 ± 2.4 b Anemia, No. (%) Hb <11 g/dl 43 (37.7) 50 (52.6) Hb <12 g/dl 62 (54.3) MCV, fl 89.8 ± ± 9.4 RET-He, pg/cell 33.2 ± ± 4.5 Serum iron, µg/dl 92.9 ± ± 63.9 Transferrin saturation, % 31.9 ± ± 21.0 Ferritin, ng/ml 392 ± ± 650 Hb, hemoglobin; MCV, mean corpuscular volume; RET-He, hemoglobin content of reticulocytes. a Values are presented as mean ± SD unless otherwise indicated. b Statistically significant difference (P <.05). No. of Patients < RET-He (pg) >41 Figure 1 Distribution of the hemoglobin content of reticulocytes (RET-He) in the study population. The solid line indicates the reference range for RET-He: 28 to 36 pg. observed between males and females (P =.831) (Table 1). Values ranged from 19.7 to 47.6 pg. Although reference intervals vary among published series, RET-He values ranging from 28 to 36 pg are generally considered normal. 28,31 The distribution of RET-He values for the current patient population was shifted to the right because of an increase in the number of patients with macrocytic RBCs (95% confidence interval for MCV, fl). Macrocytosis has been correlated with an increased RET-He. 31 RET-He is a measure of the amount of Hb in reticulocytes and as such has been identified as a convenient indicator of iron-deficient and iron-restricted erythropoiesis. In the current study, statistically significant differences (P <.05) in Hb, MCV, serum iron, and transferrin saturation were noted when comparing patients with RET-He levels above and below the published normal population reference range of 28 pg Table 2. Consistent with observations that ferritin is of limited value as an indicator of iron status in patients with cancer, 33 serum ferritin did not correlate significantly with RET-He or Hb (P =.20) and even showed an inverse relationship with RET-He, suggesting inflammation and chronic disease and/or the presence of tumor-derived ferritin. 27,33 In the current study of 209 patients, 93 were anemic with Hb levels less than 11 g/dl, the threshold identified by Steinmetz et al 38 for consideration of iron deficiency in oncology patients. Iron deficiency anemia was identified in 23 of these patients, based on biochemical studies, including serum iron and transferrin saturation. In contrast, only nine patients were identified with iron deficiency anemia based on the combination of decreased serum iron, transferrin saturation, and ferritin. Iron deficiency without consideration for anemia was identified in 34 patients based on decreased serum iron and transferrin saturation alone and in 18 patients based on the combination of decreased serum iron, transferrin saturation, and ferritin. Figure 2 illustrates the relationship between the sensitivity and specificity of RET-He for identifying iron deficiency, defined using biochemical standards, including serum iron less than 40 µg/dl and transferrin saturation less than 20%. An RET-He threshold of 31 to 32 pg/cell was identified, representing the 34th percentile of RET-He values in the study population. The same RET-He threshold was identified when the definition of iron deficiency was expanded to include low ferritin (<100 ng/ml) and/or low Hb less than 11 g/dl. Table 3 summarizes the ability of RET-He at thresholds of 31 and 32 pg to rule out iron deficiency in the study patient population. Uniformly good negative Table 2 RET-He Correlations a RET-He <28 pg RET-He 28 pg Characteristic Mean (SD) Median Mean (SD) Median P Value Hb, g/dl 9.1 (2.3) (2.6) MCV, fl 82.3 (8.2) (7.4) Ferritin, ng/ml 567 (752) (724) Serum iron, µg/dl 55.5 (50.3) (518) Transferrin saturation, % 26 (24.5) (20.8) Hb, hemoglobin; MCV, mean corpuscular volume; RET-He, hemoglobin content of reticulocytes. a RET-He threshold of 28 pg represents the lower limit of the reference range. 508 Am J Clin Pathol 2014;142: Downloaded 508 from
4 Sensitivity, Specificity Sensitivity Specificity RET-He (pg) Figure 2 Comparison of the sensitivity and specificity of the hemoglobin content of reticulocytes (RET-He) at different thresholds for the identification of iron deficiency defined by the combination of serum iron less than 40 µg/dl and transferrin saturation less than 20% in a diverse oncology patient population. The circled area represents the clinically significant cutoff. predictive values were noted. No difference in RET-He performance was found when applied to the evaluation of male and female patients. Indeed, RET-He performance was better (negative predictive value of 98.5%) than that of traditional CBC parameters (negative predictive value of 88.5%), consisting of MCV less than 80 fl, and Hb less than 11 g/dl for women or less than 12 g/dl for men. However, the positive predictive value of an abnormal RET-He result was low because of the high selected cutoff and the high rate of inflammation and chronic disease, leading to ironrestricted hematopoiesis in the study population. In a subanalysis of patients with iron deficiency, defined by serum iron less than 40 µg/dl and transferrin saturation less than 20%, iron deficiency was missed in three of 23 patients using an RET-He cutoff of less than 32 pg. Interestingly, the three observed false-negative cases would not have been characterized as iron deficient using in-house reference ranges for serum iron (34 µg/dl). When serum ferritin (<100 ng/ml) was included in the definition of iron deficiency, RET-He missed two of nine patients with biochemical iron deficiency. These two false-negative cases did not meet criteria for anemia (Hb of 15.7 and 11.7 g/dl), and ferritin was normal by in-house reference ranges (<22 ng/ml for males and <6 ng/ml for females). Similarly, when monitoring patients (n = 15) receiving oral iron supplementation, RET-He (<32 pg) identified two of two patients with residual iron deficiency. However, three of 13 patients, who were deemed iron replete based on biochemical studies, were classified as iron deficient by the high RET-He cutoff. Finally, RET-He (<32 pg) ruled out iron deficiency (serum iron <40 µg/ml and transferrin saturation <20%, with or without ferritin <100 ng/ml) with a negative predictive value of 100% in patients (n = 19) with low reticulocyte counts (< /L). Given the small sample size, additional prospective studies are required to confirm RET-He performance in these settings. Table 3 Performance of RET-He or the Combination of Hb and MCV in the Evaluation of Iron Deficiency/Iron Deficiency Anemia MCV Negative Predictive Positive Predictive Condition RET-He and Hb Sensitivity Specificity Value, % Value, % Iron deficiency Transferrin saturation < <20% and serum iron <40 µg/dl < Transferrin saturation < <20% and serum iron <40 µg/dl and ferritin < <100 ng/ml Iron deficiency anemia Hb <11 g/dl with transferrin < saturation <20%, serum iron <40 µg/dl, and ferritin < <100 ng/ml Transferrin saturation <20% Hb <11 g/dl (F) and serum iron <40 µg/dl and or <12 g/dl (M) and ferritin <100 ng/ml MCV <80 fl Hb, hemoglobin; MCV, mean corpuscular volume; RET-He, hemoglobin content of reticulocytes. Hb <11 g/dl and MCV <80 fl Downloaded from Am J Clin Pathol 2014;142:
5 Peerschke et al / RET-He and Anemia Discussion Anemia is a major cause of morbidity in patients with cancer. There are multiple causative factors, including absolute iron deficiency due to blood loss and/or nutritional deficiencies, anemia of chronic disease, and myelosuppressive effects of chemotherapy, as well as metastatic infiltration of the bone marrow. The identification of iron deficiency in patients with cancer is particularly important in patients being considered for therapy with erythropoiesis-stimulating agents Approximately 30% to 50% of patients with cancer with chemotherapy-related anemia have been reported to experience poor to absent responses to erythropoiesisstimulating agents, 41,42 and iron therapy has been shown to improve the response in some of these patients. In addition, iron therapy has been associated with a reduction in the RBC transfusion requirements in women with gynecologic cancers treated with chemoradiotherapy. 43,44 Since the identification of iron deficiency has important therapeutic implications in oncology patients, current recommendations are to investigate the cause of anemia if the Hb falls below 11 g/dl. 38,39,45 The present study supports the use of RET-He to rapidly rule out iron deficiency, defined by traditional serum biochemical markers, in a complex patient population with cancer, during routine automated CBC and reticulocyte analysis. To evaluate RET-He in the broadest possible oncology population, we did not stratify patients by malignancy, staging, treatment, or transfusion therapy. In this unselected patient population with cancer, a high negative predictive value for ruling out iron deficiency was achieved using an RET-He cutoff of 31 to 32 pg, when iron deficiency was defined by serum iron and transferrin saturation, with or without ferritin. In this setting, RET-He outperformed the combination of Hb and MCV. The MCV (mean RBC volume) is of limited utility in oncology patients, because is it observed in the later stages of iron deficiency and is influenced by reticulocytosis, 20 liver disease, myelodysplastic syndrome, aplasia, myelofibrosis, and impaired DNA synthesis and cell division due to chemotherapy. 50 Despite the excellent negative predictive value of RET- He for ruling out iron deficiency in the present study, the corresponding specificity was low. This was expected based on the high selected RET-He threshold relative to established reference ranges 28,31 and the high incidence of anemia of chronic disease in the oncology population. All false-positive cases identified by an RET-He threshold of 32 pg (n = 50) were examined by chart review. Indeed, in 40 cases, the anemia was characterized as anemia of chronic disease in the patient record. Since anemia of chronic disease is characterized by ironrestricted hematopoiesis, RET-He levels are expected to be low and to overlap with those found in iron deficiency. 23 In the remaining 10 cases with falsely positive RET- He values and normal biochemical iron studies, one case of a hemoglobinopathy combined with b-thalassemia trait (heterozygous Hb Mississippi/b-thalassemia) was identified with expected low RET-He, 30 two patients were found to be iron deficient by biochemical tests on a follow-up visit, and seven patients had borderline serum iron (<45 µg/dl) and transferrin saturation (<25%). Further studies are required to determine how well RET-He distinguishes iron-deficient or iron-restricted hematopoiesis from bone marrow suppression. Data from a small subanalysis of patients with low reticulocyte counts in the present study appear promising. The hemoglobin content of erythrocytes, measured either as ADVIA 2120 CHr or Sysmex RET-He, has been reported to be a reliable indicator of iron-deficient erythropoiesis in diverse patient populations, including pediatrics, geriatrics, pregnancy, and particularly chronic kidney disease Its performance characteristics in evaluating anemia in patients with cancer, however, are not well understood. This study provides insight into the utility of measuring RET-He in an oncology setting, in which patients are routinely monitored for cytopenias, typically in an outpatient setting. Biochemical iron studies are often ordered in conjunction with a CBC and other laboratory tests as part of automated order sets designed to expedite the interpretation of anemia in patients at risk. Thus, the ability to obtain information regarding the availability of iron for erythropoiesis, as part of routine peripheral blood CBC and reticulocyte analysis, performed in an outpatient setting before the patient is evaluated by a specialist, would significantly benefit patient management. To focus on patients at risk for iron deficiency, we evaluated RET-He only in patients with orders for CBC and serum iron studies. This method may have introduced an unintended bias into the analysis, since only those patients who had further laboratory studies ordered were included in the current study. This limitation precludes understanding the role of RET-He in a broader patient population with cancer. Other limitations of the study include the small number of patients who actually had iron deficiency anemia, in the context of a significant population with iron-restricted erythropoiesis secondary to inflammation and chronic disease. In addition, the diagnosis of iron deficiency was inferred from biochemical studies and medical record review, in the absence of a gold standard for iron deficiency such as bone marrow iron studies. Standard biochemical tests of iron metabolism, such as serum iron, ferritin, and transferrin, are affected by the acute phase response. During the acute phase, serum iron and ferritin are increased, whereas transferrin is decreased Therefore biochemical markers of iron status are less than ideal standards for diagnosing iron deficiency. In current clinical practice, however, bone marrow evaluation to assess iron status is not performed in most patients with cancer who have anemia, and iron deficiency is diagnosed based on results of serum iron studies. 510 Am J Clin Pathol 2014;142: Downloaded 510 from
6 In summary, the data support the use of RET-He to rapidly rule out iron-deficient erythropoiesis, reduce unnecessary iron studies, and provide rapid diagnostic information when the automated CBC and reticulocyte counts are reported. Based on data from the present study, using RET-He to rule out iron deficiency would reduce the number of required iron studies by 66% (from 209 to 70) at our center. If a combination of RET-He (<32 pg) and anemia (Hb <11 g/dl) were used to rule out iron deficiency anemia, the number of required iron studies would decrease by approximately 80% (from 209 to 43). Since RET- He and its CHr equivalent are routinely available with automated reticulocyte analysis on Sysmex XE/XN series and Siemens ADVIA hematology analyzers, respectively, this parameter can be integrated readily into the diagnostic algorithm of anemia evaluations. RET-He and CHr cutoff values reported for the identification of iron deficiency vary widely in the literature, from 26 to 33 pg, depending on the study patient population. 3-11,51 Thus, customizing the RET-He threshold to rule out iron deficiency in specific patient populations is recommended. Of note, the RET-He threshold of 32 pg/cell, selected in the present study to rule out iron deficiency, was applicable also to an independent study cohort described by Canals et al 23 to correctly rule out iron deficiency anemia and iron-restricted hematopoiesis. Address reprint requests to Dr Peerschke: Dept of Laboratory Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, S317, New York, NY 10065; peersche@mskcc.org. This work was supported in part by funds from Sysmex America (Lincolnshire, IL). Acknowledgment: We thank Nenita Francisco for expert technical assistance. References 1. Brugnara C, Mohandas N. Red cell indices in classification and treatment of anemias: from M.M. Wintrobes s original 1934 classification to the third millennium. Curr Opin Hematol. 2013;20: Brugnara C, Schiller B, Moran J. Reticulocyte hemoglobin equivalent (Ret He) and assessment of iron-deficient states. Clin Lab Haematol. 2006;28: Buttarello M, Pajola R, Novello E, et al. Diagnosis of iron deficiency in patients undergoing hemodialysis. Am J Clin Pathol. 2010;133: Garzia M, Di Mario A, Ferraro E, et al. Reticulocyte hemoglobin equivalent: an indicator of reduced iron availability in chronic kidney diseases during erythropoietin therapy. Lab Hematol. 2007;13: Torsvik IK, Markestad T, Ueland PM, et al. Evaluating iron status and the risk of anemia in young infants using erythrocyte parameters. Pediatr Res. 2013;73: Semmelrock MJ, Raggam RB, Amrein K, et al. Reticulocyte hemoglobin content allows early and reliable detection of functional iron deficiency in blood donors. Clin Chim Acta. 2012;413: Joosten E, Lioen P, Brusselmans C, et al. Is analysis of the reticulocyte haemoglobin equivalent a useful test for the diagnosis of iron deficiency anaemia in geriatric patients? Eur J Int Med. 2013;24: Karlsson T. Comparative evaluation of the reticulocyte hemoglobin content assay when screening for iron deficiency in elderly anemic patients. Anemia. 2011;2011: Schoorl M, Schoorl M, van der Gaag D, et al. Effects of iron supplementation on red blood cell hemoglobin content in pregnancy. Hematol Rep. 2012;4:e Miwa N, Akiba T, Kimata N, et al. Usefulness of measuring reticulocyte hemoglobin equivalent in the management of haemodialysis patients with iron deficiency. Int J Lab Hematol. 2010;32: Urrechaga E, Borque L, Escanero JF. Erythrocyte and reticulocyte indices in the assessment of erythropoiesis activity and iron availability. Int J Lab Hematol. 2013;35: Brugnara C, Laufer MR, Friedman AJ, et al. Reticulocyte hemoglobin content (CHr): early indicator of iron deficiency and response to therapy. Blood. 1994;83: Major A, Mathez-Loic F, Rohling R, et al. The effect of intravenous iron on the reticulocyte response to recombinant human erythropoietin. Br J Haematol. 1997;98: Chuang CL, Liu RS, Wei YH, et al. Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients. Nephrol Dial Transplant. 2003;18: Fishbane S, Galgano C, Langley RC Jr, et al. Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int. 1997;52: Fishbane S, Shapiro W, Dutka P, et al. A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int. 2001;60: Mittman N, Sreedhara R, Mushnick R, et al. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rhuepo. Am J Kidney Dis. 1997;30: Tsuchiya K, Okano H, Teramura M, et al. Content of reticulocyte hemoglobin is a reliable tool for determining iron deficiency in dialysis patients. Clin Nephrol. 2003;59: Brittenham GM, Weiss G, Brissot P, et al. Clinical consequences of new insights in the pathophysiology of disorders of iron and heme metabolism. Am Soc Hemat Ed Prog. 2000;95: Doig K. Disorders of iron metabolism. In: Rodak B, ed. Hematology: Clinical Principles and Applications. 2nd ed. Philadelphia, PA: Saunders; Guyatt GH, Oxman AD, Ali M, et al. Laboratory diagnosis of iron-deficiency anemia: an overview. J Gen Intern Med. 1992;7: Rehu M, Ahonen S, Punnonen K. The diagnostic accuracy of the percentage of hypochromic red blood cells (%HYPOm) and cellular hemoglobin in reticulocytes (CHr) in differentiating iron deficiency anemia and anemia of chronic diseases. Clin Chim Acta. 2011;412: Canals C, Remacha AF, Sarda MP, et al. Clinical utility of the new Sysmex XE 2100 parameter reticulocyte hemoglobin equivalent in the diagnosis of anemia. Haematology. 2005;90: Van Wyck DB, Alcorn H Jr, Gupta R. Analytical and biological variation in measures of anemia and iron status in patients treated with maintenance hemodialysis. Am J Kidney Dis. 2010;56: Downloaded from Am J Clin Pathol 2014;142:
7 Peerschke et al / RET-He and Anemia 25. Mast AE, Blinder MA, Dietzen DJ. Reticulocyte hemoglobin content. Am J Hematol. 2008;83: Brugnara C, Zelmanovic D, Sorette M, et al. Reticulocyte hemoglobin: an integrated parameter for evaluation of erythropoietic activity. Am J Clin Pathol. 1997;108: Brugnara C. Reticulocyte cellular indices: a new approach in the diagnosis of anemias and monitoring of erythropoietic function. Crit Rev Clin Lab Sci. 2000;37: Brugnara C. Iron deficiency and erythropoiesis: new diagnostic approaches. Clin Chem. 2003;49: Buttarello M, Temporin V, Ceravolo R, et al. The new reticulocyte parameter (RET-Y) of the Sysmex XE 2100: its use in the diagnosis and monitoring of posttreatment sideropenic anemia. Am J Clin Pathol. 2004;121: Skarmoutsou C, Papassotiriou I, Traeger-Synodinos J, et al. Erythroid bone marrow activity and red cell hemoglobinization in iron sufficient beta-thalassemia heterozygotes as reflected by soluble transferrin receptor and reticulocyte hemoglobin in content: correlation with genotypes and Hb A(2) levels. Haematologica. 2003;88: Mast AE, Blinder MA, Lu Q, et al. Clinical utility of the reticulocyte hemoglobin content in the diagnosis of iron deficiency. Blood. 2002;99: Ervasti M, Kotisaari S, Heinonen S, et al. Use of advanced red blood cell and reticulocyte indices improves the accuracy in diagnosing iron deficiency in pregnant women at term. Eur J Haematol. 2007;79: Alkhateeb AA, Connor JR. The significance of ferritin in cancer: anti-oxidation, inflammation and tumorigenesis. Biochim Biophys Acta. 2013;1836: World Health Organization. Serum ferritin concentrations for the assessment of iron status and iron deficiency in populations. Vitamin and Mineral Nutrition Information System pdf. Accessed October Altman DG, Bland JM. Diagnostic tests 1: sensitivity and specificity. BMJ. 1994;308: Loong TW. Understanding sensitivity and specificity with the right side of the brain. BMJ. 2003;327: Altman DG, Bland JM. Diagnostic tests 2: predictive values. BMJ. 1994;309: Steinmetz HT. The role of intravenous iron in the treatment of anemia in cancer patients. Ther Adv Hematol. 2012;3: Steinmetz HT, Tsamaloukas A, Schmitz S, et al. A new concept for the differential diagnosis and therapy of anaemia in cancer patients. Support Care Cancer. 2010;19: Steinmetz T, Hellmich M, Neise M, et al. Prediction of the responsiveness to treatment with erythropoiesis-stimulating factors: a prospective clinical study in patients with solid tumors. Oncologist. 2007;12: Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol. 1997;15: Littlewood TJ, Bajetta E, Nortier JW, et al; Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, doubleblind, placebo-controlled trial. J Clin Oncol. 2001;19: Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol. 2010;116: Kim YT, Kim SW, Yoon BS, et al. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol. 2007;105: Rizzo JD, Brouwers M, Hurley P, et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood. 2010;116: Holyoake TL, Stott DJ, McKay PJ, et al. Use of plasma ferritin concentration to diagnose iron deficiency in elderly patients. J Clin Pathol. 1993;46: Leers MP, Keuren JF, Oosterhuis WP. The value of the Thomas-plot in the diagnostic work up of anemic patients referred by general practitioners. Int J Lab Hematol. 2010;32(6, pt 2): Markovic M, Majkic-Singh N, Ignjatovic S, et al. Reticulocyte haemoglobin content vs. soluble transferrin receptor and ferritin index in iron deficiency anaemia accompanied with inflammation. Int J Lab Hematol. 2007;29: Wong SS, Qutishat AS, Lange J, et al. Detection of iron-deficiency anemia in hospitalized patients by zinc protoporphyrin. Clin Chim Acta. 1996;244: Bozkurt O, Berk V, Kaplan MA, et al. Lack of prognostic value of mean corpuscular volume with capecitabine therapy in metastatic breast cancer. Asian Pac J Cancer Prev. 2014;15: Urrechaga E, Borque L, Escanero JF. Potential utility of the new Sysmex XE 5000 red blood cell extended parameters in the study of disorders of iron metabolism. Clin Chem Lab Med. 2009;47: Am J Clin Pathol 2014;142: Downloaded 512 from
Utilizing Sysmex RET He to Evaluate Anemia in Cancer Patients
Utilizing Sysmex RET He to Evaluate Anemia in Cancer Patients Ellinor I. Peerschke, Ph.D., F.A.H.A. Vice Chair, Laboratory Medicine Chief, Hematology & Coagulation Laboratory Services Memorial Sloan Kettering
More informationJournal of Global Pharma Technology
Journal of Global Pharma Technology ISSN 0975-8542 Available Online at www.jgpt.co.in RESEARCH ARTICLE Reticulocyte Hemoglobin Equivalent (RET-HE) As A Predictor and Early Marker for Oral Iron Response
More informationResearch Article Erythrocyte and Reticulocyte Indices on the LH 750 as Potential Markers of Functional Iron Deficiency
Anemia Volume 2010, Article ID 625919, 7 pages doi:10.1155/2010/625919 Research Article Erythrocyte and Reticulocyte Indices on the LH 750 as Potential Markers of Functional Iron Deficiency Eloísa Urrechaga,
More informationCustomer Information Literature List Red Blood Cells
Customer Information Literature List Red Blood Cells Date: October 2015 Subject: Literature List Red Blood Cells Issued by: Scientific Customer Services Number: 151019 Note: Whether references are given
More informationSerum soluble transferrin receptor in hypochromic microcytic anaemia
O r i g i n a l A r t i c l e Singapore Med Med J 2006; J 2006; 47(2) 47(2) : 138 : 1 Serum soluble transferrin receptor in hypochromic microcytic anaemia Jayaranee S, Sthaneshwar P ABSTRACT Introduction:
More informationEpogen / Procrit. Epogen / Procrit (epoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.06 Section: Prescription Drugs Effective Date: April1, 2014 Subject: Epogen / Procrit Page: 1 of 7
More informationThe Role of Reticulocyte Hemoglobin Content (CHr) to Early Diagnosis Iron Deficiency Anemia
The Role of Reticulocyte Hemoglobin Content (CHr) to Early Diagnosis Iron Deficiency Anemia Delita Prihatni SMF/Dept Patologi Klinik RSUP Dr. Hasan Sadikin/ FK UNPAD BANDUNG Introduction Iron Deficiensy
More informationEffective Health Care Program
Comparative Effectiveness Review Number 83 Effective Health Care Program Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage Chronic Kidney Disease Executive Summary Background Chronic
More informationANEMIA & HEMODIALYSIS
ANEMIA & HEMODIALYSIS The anemia of CKD is, in most patients, normocytic and normochromic, and is due primarily to reduced production of erythropoietin by the kidney and to shortened red cell survival.
More informationRed Cell Indices and Functions Differentiating Patients with the β-thalassaemia Trait from those with Iron Deficiency Anaemia
The Journal of International Medical Research 2009; 37: 25 30 [first published online as 37(1) 4] Red Cell Indices and Functions Differentiating Patients with the β-thalassaemia Trait from those with Iron
More informationApril 12, Coverage of ESAs for Patients with Conditions Other than End-Stage Renal Disease
[ASH Comments to the Centers for Medicare and Medicaid Services on coverage for Erythropoiesis Stimulating Agents (ESAs) filed electronically on April 12, 2007] April 12, 2007 The American Society of Hematology
More informationErythropoiesis Stimulating Agents (ESA)
Erythropoiesis Stimulating Agents (ESA) Policy Number: Original Effective Date: MM.04.008 04/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 06/01/2015 Section: Prescription
More informationUpdate on Chemotherapy- Induced Anemia and Neutropenia Therapies
Update on Chemotherapy- Induced Anemia and Neutropenia Therapies ASCO 2007: Update on Chemotherapy- Induced Anemia and Neutropenia Therapies Safety and efficacy of intravenous iron in patients with chemotherapyinduced
More informationAranesp. Aranesp (darbepoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.01 Subject: Aranesp Page: 1 of 6 Last Review Date: September 15, 2017 Aranesp Description Aranesp
More informationMicrocytic Hypochromic Anemia An Approach to Diagnosis
Microcytic Hypochromic Anemia An Approach to Diagnosis Decreased hemoglobin synthesis gives rise to microcytic hypochromic anemias. Hypochromic anemias are characterized by normal cellular proliferation
More informationEvidence-Based Hematological Solutions
Evidence-Based Hematological Solutions Beyond the Routine CBC Objectives Describe novel hematology parameters and their derivation. Investigate the evidence for their clinical utility. Discuss how new
More information5/1/2017 DISCUSSION POINTS. Clinical Utility of Immature Cell Indices Beyond the Routine CBC John E. Donnelly BSN, RN
DISCUSSION POINTS Importance of hematological immature cell indices Clinical Utility of Immature Cell Indices Beyond the Routine CBC John E. Donnelly BSN, RN Investigate the evidence for clinical utility:
More informationAETNA BETTER HEALTH Prior Authorization guideline for Erythropoiesis Stimulating Agents (ESA)
AETNA BETTER HEALTH Prior Authorization guideline for Erythropoiesis Stimulating Agents (ESA) Drugs Covered Procrit Epogen Aranesp Authorization guidelines For patients who meet all of the following: Does
More informationManagement of anemia in CKD
Management of anemia in CKD Pierre Cochat, MD PhD Professor of Pediatrics Chair, Pediatrics & Pediatric Surgery Department Head, Center for Rare Renal Diseases Néphrogones Hospices Civils de Lyon & University
More informationBrief Communication: Sensitivity, Specificity, and Predictive Value of Serum Soluble Transferrin Receptor at Different Stages of Iron Deficiency
Available online at www.annclinlabsci.org Annals of Clinical & Laboratory Science, vol. 35, no. 4, 2005 435 Brief Communication: Sensitivity, Specificity, and Predictive Value of Serum Soluble Transferrin
More informationIntravenous Iron: A Good Thing Made Better? Marilyn Telen, MD Wellcome Professor of Medicine Duke University
Intravenous Iron: A Good Thing Made Better? Marilyn Telen, MD Wellcome Professor of Medicine Duke University Use of IV Iron There are increasing data regarding safety of IV iron. IV iron is superior to
More informationM. Velizarova, T. Yacheva and K. Tzatchev Department of Clinical Laboratory and Clinical Immunology, MU Sofia
50, 48, 2012, 3, ADVIA 2120.,.., ANALYSIS OF DIAGNOSTIC RED CELL CYTOGRAMS, GENERATED BY THE ADVIA 2120 HEMATOLOGY ANALYZER M. Velizarova, T. Yacheva and K. Tzatchev Department of Clinical Laboratory and
More informationLOOKING BACK TO OUR ROOTS: 80 YEARS OF WINTROBE S INDICES
LOOKING BACK TO OUR ROOTS: 80 YEARS OF WINTROBE S INDICES *Eloísa Urrechaga, 1 Silvia Izquierdo, 2 Jesús F. Escanero 3 1. Laboratory, Hospital Galdaka-Usansolo, Hematology Laboratory, Galdakao, Spain 2.
More informationIntravenous Iron Requirement in Adult Hemodialysis Patients
Intravenous Iron Requirement in Adult Hemodialysis Patients Timothy V. Nguyen, PharmD The author is a clinical pharmacy specialist with Holy Name Hospital in Teaneck, New Jersey. He is also an adjunct
More information10/15/2015. Clinical Utility of Immature Cell Indices DISCUSSION POINTS HEALTHCARE REFORM PAYMENT MODEL EXPERIMENTS
Clinical Utility of Immature Cell Indices Leveraging Technology to Help Manage Anemia and Blood Utilization donnellyj@sysmex.com 2015 Sysmex America, Inc. All rights reserved. For Clinical Support Team
More informationANEMIA IN CANCER ROLE OF IV IRON
ANEMIA IN CANCER ROLE OF IV IRON IRON DEFICIENCY Absolute vs functional Absolute iron deficiency µ anemia = no iron stores : ferritin < 20 µg/l in N individual < 100 µg/l in infl/cancer patient Functional
More informationABSTRACT. Keywords: Chemotherapy induced anaemia, gastrointestinal cancers, India.
An Open Labeled Two Arm Study to Evaluate the Feasibility, Quality of Life, Safety and Efficacy of Darbepoetin as Compared to Erythropoietin Inpatients with Chemotherapy Induced Anemia in Patients with
More informationIron Supplementation and Erythropoiesis-Stimulatory Agents in the Treatment of Cancer Anemia
Iron Supplementation and Erythropoiesis-Stimulatory Agents in the Treatment of Cancer Anemia Paolo Pedrazzoli, MD 1, Giovanni Rosti, MD 2, Simona Secondino, MD 1, and Salvatore Siena, MD 1 Unresponsiveness
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Darbepoetin Alfa (Aranesp) Reference Number: CP.PHAR.236 Effective Date: 06.01.16 Last Review Date: 05.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important
More informationMedication Prior Authorization Form
Procrit, Aranesp and (Epoetin Alfa) Policy Number: 1043 Policy History Approve Date: 12/11/2015 Effective Date: 12/11/2015 Preauthorization All Plans Benefit plans vary in coverage and some plans may not
More informationA New Dose-intense Epoetin Alfa Regimen Effective in Anemic Cancer Patients Receiving Chemotherapy: An Open-label, Non Randomized, Pilot Study
A New Dose-intense Epoetin Alfa Regimen Effective in Anemic Cancer Patients Receiving Chemotherapy: An Open-label, Non Randomized, Pilot Study DANIELE SANTINI 1, BRUNO VINCENZI 1, ANNALISA LA CESA 1, VLADIMIR
More informationThe. JOHN GLASPY, a,e LAURENT DEGOS, b,e MARIO DICATO, c,e GEORGE D. DEMETRI d,e LEARNING OBJECTIVES ABSTRACT
The Oncologist Comparable Efficacy of Epoetin Alfa for Anemic Cancer Patients Receiving Platinum- and Nonplatinum-Based Chemotherapy: A Retrospective Subanalysis of Two Large, Community-Based Trials JOHN
More informationK atching Up with KDOQI: Clinical Practice Guidelines & Clinical Practice Recommendations for Anemia of Chronic Kidney Disease 2006
K atching Up with KDOQI: Clinical Practice Guidelines & Clinical Practice Recommendations for Anemia of Chronic Kidney Disease 2006 Why new guidelines? Rationale for KDOQI Anemia 2006 Expand scope to all
More informationAssessing Iron Deficiency in Adults. Chris Theberge. Iron (Fe) deficiency remains as one of the major global public health problems for
Assessing Iron Deficiency in Adults Chris Theberge Iron (Fe) deficiency remains as one of the major global public health problems for two reasons. It affects about one fourth of the world s population
More informationOral Iron Safe, Effective, and Misunderstood Duke Debates 2017
Oral Iron Safe, Effective, and Misunderstood Duke Debates 2017 John Strouse, MD, PhD Instructor (temp) Medicine and Pediatrics Director, Adult Sickle Cell Program April 20, 2017 1 Disclosures I have no
More informationBrief Communication: Association of Serum Insulin-Like Growth Factor-I and Erythropoiesis in Relation to Body Iron Status
324 Annals of Clinical & Laboratory Science, vol. 34, no. 3, 2004 Brief Communication: Association of Serum Insulin-Like Growth Factor-I and Erythropoiesis in Relation to Body Iron Status Jong Weon Choi
More informationEmilia Parodi, 1 Maria Teresa Giraudo, 2 Fulvio Ricceri, 3 Maria Luigia Aurucci, 4 Raffaela Mazzone, 5 and Ugo Ramenghi 4. 1.
Anemia Volume 2016, Article ID 7345835, 6 pages http://dx.doi.org/10.1155/2016/7345835 Research Article Absolute Reticulocyte Count and Reticulocyte Hemoglobin Content as Predictors of Early Response to
More informationEffective Health Care
Number 3 Effective Health Care Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment Executive Summary Background Anemia (deficiency of red blood
More informationESM Table 2 Data extraction form and key data from included studies
ESM Table 2 Data extraction form and key data from included studies Author, year and title Behan, 2006 [21] Cessation of menstruation improves the correlation of FPG to hemoglobin A 1c in Caucasian women
More informationReview Article Biomarkers of Hypochromia: The Contemporary Assessment of Iron Status and Erythropoiesis
BioMed Research International Volume 2013, Article ID 603786, 8 pages http://dx.doi.org/10.1155/2013/603786 Review Article Biomarkers of Hypochromia: The Contemporary Assessment of Iron Status and Erythropoiesis
More informationAbbott Cell-Dyn Reticulocyte Method Comparison and Reticulocyte Normal Reference Range Evaluation
Laboratory Hematology 8:85-90 2002 Carden Jennings Publishing Co.. Ltd. Abbott Cell-Dyn Reticulocyte Method Comparison and Reticulocyte Normal Reference Range Evaluation T. SCHISANO, L. VAN HOVE Abbott
More informationUpdates in the Management of Anemia in Cancer. Taylor M. Ortiz, MD May 19, 2017
Updates in the Management of Anemia in Cancer Taylor M. Ortiz, MD May 19, 2017 Objectives Recall common causes of anemia in patients with cancer Understand risks/benefits of blood transfusion in patients
More informationIRON DEFICIENCY IS THE MOST COMmon
ORIGINAL CONTRIBUTION Screening Healthy Infants for Deficiency Using Reticulocyte Content Christina Ullrich, MD Ann Wu, MD Carrie Armsby, MD Sarah Rieber, MPH Sarah Wingerter, MD Carlo Brugnara, MD David
More informationYear 2003 Paper two: Questions supplied by Tricia
QUESTION 65 A 36-year-old man presents in a post-ictal state after an observed generalised seizure. Full blood investigation shows: haemoglobin 0 g/l [128-175] mean corpuscular volume (MCV) 106 fl [80-7]
More informationIron Deficiency Anaemia but Why? Dr LAU Ching-wa Specialist in Haematology Blood Transfusion Service
Iron Deficiency but Why? Dr LAU Ching-wa Specialist in Haematology Blood Transfusion Service 1 3 Questions 1. Is anaemia incurable in my patient? 2. Is anaemia unavoidable in my bleeding patient? 3. Is
More informationAutomated Quantitation of Hemoglobin-Based Blood Substitutes in Whole Blood Samples
Hematopathology / HEMOGLOBIN-BASED BLOOD SUBSTITUTES Automated Quantitation of Hemoglobin-Based Blood Substitutes in Whole Blood Samples Jolanta Kunicka, PhD, 1 Michael Malin, PhD, 1 David Zelmanovic,
More informationThe Nucleated Red Blood Cell (NRBC) Count in Thalassaemia Syndromes Paolo Danise and Giovanni Amendola
7. The Nucleated Red The Nucleated Red Blood Cell (NRBC) Count in Thalassaemia Syndromes Paolo Danise and Giovanni Amendola Introduction The purpose of this study was to evaluate the performance of the
More informationAnaemia & Cancer. John de Vos Consultant Haematologist RSCH
Anaemia & Cancer John de Vos Consultant Haematologist RSCH overview Definitions & setting the scene Causes Consequences Biology Treatment Personal approach Patient Clinical team Anaemia - Definition :
More informationAnemia Management in Peritoneal Dialysis Patients Pranay Kathuria, FACP, FASN
Anemia Management in Peritoneal Dialysis Patients Pranay Kathuria, FACP, FASN Professor of Medicine Director, Division of Nephrology and Hypertension University of Oklahoma College of Medicine Definition
More informationOPTA-therapy with iron and erythropoiesis-stimulating agents in chronic kidney disease
Nephrol Dial Transplant (2007) 22 [Suppl 3]: iii2 iii6 doi:10.1093/ndt/gfm014 OPTA-therapy with iron and erythropoiesis-stimulating agents in chronic kidney disease W. H. Ho rl 1, I. C. Macdougall 2, J.
More informationPredictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation
http://www.kidney-international.org & 2007 International Society of Nephrology original article Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low
More informationRaeda T. Al-Ghananim, 1 Demet Nalbant, 1 Robert L. Schmidt, 1 Gretchen A. Cress, 1 M. Bridget Zimmerman, 2 and John A. Widness 1
Journal of Clinical Laboratory Analysis 30: 326 334 (2016) Reticulocyte Hemoglobin Content During the First Month of Life in Critically Ill Very Low Birth Weight Neonates Differs From Term Infants, Children,
More informationAnemia of Chronic Disease
J KMA Special Issue Anemia of Chronic Disease Chul Soo Kim, MD Department of Internal Medicine, Inha University College of Medicine Email : cskimmd@inha.ac.kr J Korean Med Assoc 2006; 49(10): 920-6 Abstract
More informationErythropoiesis Stimulating Agents (ESAs): Epoetin Alfa * DIALYSIS *
Erythropoiesis Stimulating Agents (ESAs): Epoetin Alfa * DIALYSIS * DESCRIPTION Erythropoietin is a glycoprotein produced in the kidneys responsible for the stimulation of red blood cell production. Epoetin
More informationHMO: Medical (provider setting); Rx (out patient) PPO/CDHP: Rx
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Epogen, Procrit (epoetin alfa, injection) Commercial HMO/PPO/CDHP
More informationIron deficiency in gastrointestinal oncology
INVITED REVIEW Annals of Gastroenterology (2014) 27, 1-6 Iron deficiency in gastrointestinal oncology Kristof Verraes, Hans Prenen University Hospitals Leuven, Belgium Abstract Anemia is a very common
More informationDrug Class Prior Authorization Criteria Erythropoiesis Stimulating Agents (ESAs)
Drug Class Prior Authorization Criteria Erythropoiesis Stimulating Agents (ESAs) Line of Business: Medicaid P & T Approval Date: May 16, 2018 Effective Date: July 1, 2018 This policy has been developed
More informationApport diagnostique des nouveaux indices érythrocytaires dans l anémie
Apport diagnostique des nouveaux indices érythrocytaires dans l anémie Dr Elena Lazarova Hôpital Erasme, Université Libre de Bruxelles, CORATA Belgique 2 ème congrès de Biologie Clinique 02/10/2014 Modern
More informationDiagnostic Approach to Patients with Anemia
J KMA Special Issue Diagnostic Approach to Patients with Anemia Seonyang Park, MD Department of Internal Medicine, Seoul National University College of Medicine E mail : seonpark@snu.ac.kr J Korean Med
More informationAnemia in the elderly. Nattiya Teawtrakul MD., PhD
Anemia in the elderly Nattiya Teawtrakul MD., PhD Contents Definition of anemia in the elderly The impact of anemia in the elderly Etiology of anemia in the elderly Management of anemia in the elderly
More informationHematology Measure #2: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy
Hematology Measure #2: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy This measure may be used as an Accountability measure Clinical Performance
More informationBONE MARROW PERIPHERAL BLOOD Erythrocyte
None Disclaimer Objectives Define anemia Classify anemia according to pathogenesis & clinical significance Understand Red cell indices Relate the red cell indices with type of anemia Interpret CBC to approach
More informationUsefulness of Reticulocyte Hemoglobin Equivalent in Management of Regular Hemodialysis Patients with Iron Deficiency Anemia
ORIGINAL ARTICLES Usefulness of Reticulocyte Hemoglobin Equivalent in Management of Regular Hemodialysis Patients with Iron Deficiency Anemia NAOMI NIARI DALIMUNTHE 1, ABDURRAHIM RASYID LUBIS 1 1 Department
More informationAnaemia in the ICU: Is there an alternative to using blood transfusion?
Anaemia in the ICU: Is there an alternative to using blood transfusion? Tim Walsh Professor of Critical Care, Edinburgh University World Health Organisation grading of the severity of anaemia Grade of
More informationHAEMATOLOGICAL EVALUATION OF ANEMIA. Sitalakshmi S Professor and Head Department of Clinical Pathology St John s medical College, Bangalore
HAEMATOLOGICAL EVALUATION OF ANEMIA Sitalakshmi S Professor and Head Department of Clinical Pathology St John s medical College, Bangalore Learning Objectives Laboratory tests for the evaluation of anemia
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Methoxy polyethylene glycol-epoetin beta (Mircera) Reference Number: CP.CPA.322 Effective Date: 06.01.18 Last Review Date: 05.18 Line of Business: Commercial Coding Implications Revision
More informationAssessing Iron Status in CKD Patients: New Laboratory Parameters
14 Assessing Iron Status in CKD Patients: New Laboratory Parameters Eloísa Urrechaga 1, Luís Borque 2 and Jesús F. Escanero 2 1 Laboratory, Hospital Galdakao, Usansolo Galdakao, Vizcaya 2 Department of
More informationNew Aspects to Optimize Epoetin Treatment with Intravenous Iron Therapy in Hemodialysis Patients
23. Berliner DialyseSeminar 1.-4. Dezember 2010 New Aspects to Optimize Epoetin Treatment with Intravenous Iron Therapy in Hemodialysis Patients George R. Aronoff, MD, MS, FACP Professor of Medicine and
More informationTopic owner: Mollie Grow MD MPH, updated June 2018
Iron deficiency Anemia UW Pediatrics Outpatient Clinical Guidelines Sources: AAP Clinical Report Diagnosis and Prevention of Iron Deficiency and Iron- Deficiency Anemia in Infants and Young Children (0
More informationNo Disclosures 03/20/2019. Learning Objectives. Renal Anemia: The Basics
Renal Anemia: The Basics Meredith Atkinson, M.D., M.H.S. Associate Professor of Pediatrics Johns Hopkins School of Medicine 16 March 2019 No Disclosures Learning Objectives At the end of this session the
More informationMarkers of iron status in chronic kidney disease
Scholarly Review Markers of iron status in chronic kidney disease Adam E. GAWEDA Department of Medicine, University of Louisville, Louisville, Kentucky, USA Abstract Anemia is one of the main comorbidities
More informationMaintenance intravenous iron therapy in pediatric hemodialysis patients Morgan H E, Gautam M, Geary D F
Maintenance intravenous iron therapy in pediatric hemodialysis patients Morgan H E, Gautam M, Geary D F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion
More informationFrequency of ABO Blood Group and Decreased Level of Hemoglobin in Lung Cancer Patients
Year: 2014; Volume: 1; Issue: 1 Article ID: CR14 02; Pages: 1-6 Advances in Cancer Research & Therapy Research Article Frequency of ABO Blood Group and Decreased Level of Hemoglobin in Lung Cancer Patients
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationPublished Online 2013 July 24. Research Article
Nephro-Urology Monthly. 2013 September; 5(4):913-7. Published Online 2013 July 24. DOI: 10.5812/numonthly.12038 Research Article Comparative Study of Intravenous Iron Versus Intravenous Ascorbic Acid for
More informationConversion Dosing Guide:
Conversion Dosing Guide: From epoetin alfa to Aranesp in patients with anemia due to CKD on dialysis Indication Aranesp (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney
More informationAssociations Between Serum Transferrin Receptor Concentrations and Erythropoietic Activities According to Body Iron Status
Annals of Clinical & Laboratory Science, vol. 33, no. 3, 2003 279 Associations Between Serum Transferrin Receptor Concentrations and Erythropoietic Activities According to Body Iron Status Jong Weon Choi
More informationPREDICTION OF RESPONSE TO OPTIMIZE OUTCOME OF TREATMENT WITH ERYTHROPOIETIN. Yves Beguin
PREDICTION OF RESPONSE TO OPTIMIZE OUTCOME OF TREATMENT WITH ERYTHROPOIETIN Yves Beguin Senior Research Associate of the National Fund for Scientific Research (FNRS, Belgium). Department of Medicine, Division
More informationClinical Policy: Darbepoetin alfa (Aranesp) Reference Number: ERX.SPMN.13
Clinical Policy: (Aranesp) Reference Number: ERX.SPMN.13 Effective Date: 10/16 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationRole of Serum Hepcidin levels in the Diagnosis of Iron Deficiency Anemia in Children in Saudi Arabia
Role of Serum Hepcidin levels in the Diagnosis of Iron Deficiency Anemia in Children in Saudi Arabia Mahmoud Mohamed Elgari*, Al-Oufi F¹, Mohammed alsalmi, M. Kurdi, NA Ibrahim, Abdelgadir Elmugadam College
More informationOnce-weekly darbepoetin alfa is as effective as three-times weekly epoetin
Artigo Original ONCE-WEEKLY DARBEPOETIN ALFA IS AS EFFECTIVE AS THREE-TIMES WEEKLY EPOETIN Rev Port Nefrol Hipert 2004; 18 (1): 33-40 Once-weekly darbepoetin alfa is as effective as three-times weekly
More informationClinical Study Serum Hepcidin Levels and Reticulocyte Hemoglobin Concentrations as Indicators of the Iron Status of Peritoneal Dialysis Patients
International Nephrology Volume 2012, Article ID 239476, 7 pages doi:10.1155/2012/239476 Clinical Study Serum Hepcidin Levels and Reticulocyte Hemoglobin Concentrations as Indicators of the Iron Status
More informationCitation for published version (APA): Nijboer, J. M. M. (2009). New insights in outcome after major trauma Groningen: s.n.
University of Groningen New insights in outcome after major trauma Nijboer, Johanna Maria Margaretha IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to
More informationIron Deficiency Anemia, β-thalassemia Minor, and Anemia of Chronic Disease. A Morphologic Reappraisal
Hematopathology / Anemias and β-thalassemia Minor Iron Deficiency Anemia, β-thalassemia Minor, and Anemia of Chronic Disease A Morphologic Reappraisal Alexandra M. Harrington, MD, MT(ASCP), 1 Patrick C.J.
More informationLaboratory diagnosis of iron deficiency: The interpretation of automated counting parameters. Dr Wayne Thomas Derriford Hospital, Plymouth
Laboratory diagnosis of iron deficiency: The interpretation of automated counting parameters. Dr Wayne Thomas Derriford Hospital, Plymouth Why does it matter? Over 30% of the Worlds population are anaemic,
More informationChapter 2. ERYTHROPOIESIS and ANEMIA
Chapter 2 ERYTHROPOIESIS and ANEMIA Red Cell Production The Production of red cells, known as erythropoiesis, is a developmental system fundamentally under genetic control but modulated and regulated by
More informationUse of mathematical indices based on CBC data to identify patients with β thalassemia minor
Revista Română de Medicină de Laborator Vol. 8, Nr. 3, Septembrie 27 7 Use of mathematical indices based on CBC data to identify patients with β thalassemia minor Trefor Higgins *, Yann Brierley 2, Annu
More informationClinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations
Clinical Chemistry 44:1 45 51 (1998) Enzymes and Protein Markers Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations Alan E. Mast, 1 Morey A.
More informationNational Institute for Health and Care Excellence
National Institute for Health and Care Excellence 2-year surveillance (2017) Chronic kidney disease: managing anaemia (2015) NICE guideline NG8 Appendix A3: Summary of new evidence from surveillance Diagnostic
More informationLiterature Scan: Erythropoiesis Stimulating Agents
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationIron Markers in Patients with Advance Chronic Kidney Disease on First Dialysis at Shaikh Zayed Hospital, Lahore
Proceeding S.Z.P.G.M.I. Vol: 29(2): pp. 83-87, 2015. Iron Markers in Patients with Advance Chronic Kidney Disease on First Dialysis at Waqar Ahmad, Muhammad Rizwan Ul Haque, Abad Ur Rehman and Sammiullah
More informationClinical and Cost Effectiveness of Darbepoetin alfa in Cancer Treatment-induced Anaemia
Clinical and Cost Effectiveness of Darbepoetin alfa in Cancer Treatment-induced Anaemia 8 th November 2004 A report for the National Institute for Clinical Excellence prepared by Amgen Ltd. EXECUTIVE SUMMARY
More informationTHE KENYA POLYTECHNIC UNIVERSITY COLLEGE
THE KENYA POLYTECHNIC UNIVERSITY COLLEGE SCHOOL OF HEALTH SCIENCES AND TECHNOLOGY DEPARTMENT OF BIOMEDICAL LABORATORY SCIENCES AND TECHNOLOGY DIPLOMA IN MEDICAL LABORATORY SCIENCE END OF YEAR 1 EXAMINATION
More informationThe effectiveness of intravenous iron for iron deficiency anemia in gastrointestinal cancer patients: a retrospective study
ORIGINAL ARTICLE Annals of Gastroenterology (2017) 30, 654-663 The effectiveness of intravenous iron for iron deficiency anemia in gastrointestinal cancer patients: a retrospective study Laurens Verhaeghe
More informationOptimization of Epoetin Therapy with Intravenous Iron Therapy in Hemodialysis Patients
J Am Soc Nephrol 11: 530 538, 2000 Optimization of Epoetin Therapy with Intravenous Iron Therapy in Hemodialysis Patients ANATOLE BESARAB,* NEETA AMIN, MUHAMMAD AHSAN,* SUSAN E. VOGEL,* GARY ZAZUWA,* STANLEY
More informationComment on European Renal Best Practice Position Statement on Anaemia Management in Chronic Kidney Disease.
Comment on European Renal Best Practice Position Statement on Anaemia Management in Chronic Kidney Disease. Goldsmith D, Blackman A, Gabbay F, June 2013 Kidney Disease: Improving Global Outcomes (KDIGO)
More informationYear 2003 Paper two: Questions supplied by Tricia
QUESTION 93 A 24-year-old woman, who has recently arrived in Australia from Vietnam, presents for evaluation of abnormal menstrual bleeding. There are no abnormalities on examination. Results of investigations
More informationNon-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.
ERYTHROPOIESIS-STIMULATING AGENTS (ESAs) Epoetin alfa (Epogen, Procrit ) Darbepoetin alfa (Aranesp ) Methoxy polyethylene glycol (PEG) epoetin-beta (Mircera ) Non-Discrimination Statement and Multi-Language
More informationTHE PREVENTION OF IRON DEFICIENCY IN BLOOD DONORS: THE ITALIAN APPROACH. Dott.ssa U. La Rocca Rome, 28 March 2019
THE PREVENTION O IRON DEICIENCY IN BLOOD DONORS: THE ITALIAN APPROACH Dott.ssa U. La Rocca Rome, 28 March 2019 MAIN CAUSES O ABSOLUTE IRON DEICIENCY/IRON DEICIENCY ANEMIA IRON DEICIENCY ANEMIA AECTS >1.2
More informationCustomer Information Literature List Platelets
Customer Information Literature List Platelets Date: August 2015 Subject: Literature List Platelets Issued by: Scientific Customer Services Number: 150803 Note: Whether references are given in British
More information